Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Hawaii Health Digest.
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
September 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 |
Press releases published on August 20, 2025
Fundraiser Invited Guests to See Ability Differently
EIN Presswire
·
August 20, 2025
Unique Easterseals Hawaii ‘Tasting in the Dark’ Event Raises $22,000 for Intellectual and Developmental Disability Programs Across the Islands HONOLULU, HI, UNITED STATES, August 20, 2025 /EINPresswire.com/ -- Guests at Easterseals Hawaii’s latest …
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
GlobeNewswire
·
August 20, 2025
Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverage Commenced commercial sales of Lisaftoclax in China, following approval …
Global Enzymes Market Set to Reach $20.4 Billion by 2029 | Asia-Pacific Emerges as a Hotspot
GlobeNewswire
·
August 20, 2025
Delray Beach, FL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- According to MarketsandMarkets, the global enzymes market is experiencing robust growth, driven by innovations in biotechnology, increasing demand in biopharmaceutical production, and rising environmental …
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
GlobeNewswire
·
August 20, 2025
CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a first-in-class degrader of the …
BioAge Labs to Present at Upcoming Investor Conferences
GlobeNewswire
·
August 20, 2025
EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human …
Olema Oncology to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 20, 2025
SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for …
Onco360® Has Been Selected as a Specialty Pharmacy Partner for HERNEXEOS® (zongertinib)
GlobeNewswire
·
August 20, 2025
LOUISVILLE, K.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Boehringer Ingelheim for Hernexeos® (Zongertinib). The Food and Drug Administration approved …
Outset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference
GlobeNewswire
·
August 20, 2025
SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will …
Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire
·
August 20, 2025
SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has closed the sale of 3,358,208 shares of its common …
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
GlobeNewswire
·
August 20, 2025
TORONTO and HAIFA, Israel, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce new preclinical imaging results providing anatomical evidence consistent with …
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
GlobeNewswire
·
August 20, 2025
– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to treat acquired …
Invivyd Announces Proposed Public Offering of Common Stock
GlobeNewswire
·
August 20, 2025
WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option …
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
GlobeNewswire
·
August 20, 2025
Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the …
APIX Biosciences NV announces new advances in Honeybee Nutrition
GlobeNewswire
·
August 20, 2025
WINGENE, Belgium, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Belgian agri-technology company APIX Biosciences NV, active in Europe and the United States, proudly announces the publication in Nature, by APIX Biosciences’ Scientific Founder Prof. Geraldine Wright and …
2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement
GlobeNewswire
·
August 20, 2025
COPENHAGEN, Denmark - August 20, 2025. Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By …
Global Big Data in Healthcare Market is Predicted to Cross the USD 330 Billion Mark by 2032 | DelveInsight
GlobeNewswire
·
August 20, 2025
New York, USA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Global Big Data in Healthcare Market is Predicted to Cross the USD 330 Billion Mark by 2032 | DelveInsight The demand for big data in healthcare is growing rapidly, fueled by the rising incidence of chronic …
Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsight
GlobeNewswire
·
August 20, 2025
New York, USA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsight The market size of Merkel cell carcinoma in the 7MM is expected to increase during the forecast period ( …
King Faisal Specialist Hospital Provides Nearly 300,000 Virtual Consultations in 2024
GlobeNewswire
·
August 20, 2025
RIYADH, Saudi Arabia, Aug. 20, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) delivered 293,381 virtual clinic visits in 2024, a 58.2% increase from the previous year. The growth highlights how telehealth has become …
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
GlobeNewswire
·
August 20, 2025
NANTES, France, August 20, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Thomas Gidoin as Chief Financial Officer. Thomas joins the Executive Committee, bringing over 15 years of deep …
OSE Immunotherapeutics nomme Thomas Gidoin au poste de Directeur Financier
GlobeNewswire
·
August 20, 2025
NANTES, France - 20 août 2025, 18 h 00 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), annonce aujourd’hui la nomination de Thomas Gidoin au poste de Directeur Financier. Thomas rejoint le Comité Exécutif, apportant à la Société plus de 15 …